US 7,456,146 B2
	Lytic peptide prodrugs
Xianxhang Yu, Mauldin, S.C. (US); and Thomas E. Wagner, Greer, S.C. (US)
Assigned to GHC Research Development Corporation, Greenville, S.C. (US)
Filed on Aug. 27, 2001, as Appl. No. 9/938,623.
Application 09/938623 is a continuation in part of application No. 09/851422, filed on May 09, 2001, granted, now 7,094,750.
Prior Publication US 2002/0045736 A1, Apr. 18, 2002
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); A61K 38/33 (2006.01); A61K 45/00 (2006.01); C07K 14/195 (2006.01); C07K 14/435 (2006.01)

U.S. Cl. 514—2  [514/12; 530/300; 530/324; 530/402; 530/820; 530/822; 530/825]

38 Claims

1. A procytotoxin comprising at least one lysine residue bound via a peptide bond to at least one amino acid via the ε-amino group of said lysine residue and further comprising a cytotoxic peptide bound to an inactivator via a peptide bond, wherein said peptide is a pore-forming cytolytic peptide that comprises an amphipathic alpha-helical structure, and wherein said peptide bond is susceptible to cleavage by PSMA.